ARGX vs IOVA
argenx SE vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | ARGX | IOVA |
|---|
| AI Score |
69
|
67
|
| Price |
$864.40
|
$6.49
|
| P/E Ratio |
31.34×
|
-9.27×
|
| ROE |
17.6%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
116.3%
|
| Debt / Equity |
0.01×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
79.2
|
| Beta |
-0.022
|
0.701
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus IOVA.
ARGX leads by 2 points.
ARGX scores 69/100 (Buy) versus IOVA at 67/100 (Buy).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical